{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:03:38Z","timestamp":1792508618061,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Astragaloside (AS)-IV, extracted from traditional Chinese medicine\n                      <jats:italic>Astragalus mongholicus<\/jats:italic>\n                      , has been widely used in the anti-inflammatory treatment for cardiovascular disease. However, the mechanism by which AS-IV affects pulmonary artery hypertension (PAH) development remains largely unknown.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Monocrotaline (MCT)-induced PAH model rats were administered with AS-IV, and hematoxylin-eosin staining and Masson staining were performed to evaluate the histological change in pulmonary tissues of rats. Pulmonary artery smooth muscle cells (PASMCs) were treated by hypoxia and AS-IV. Pyroptosis and fibrosis were assessed by immunofluorescence, western blot and enzyme-linked immunosorbent assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>AS-IV treatment alleviated pulmonary artery structural remodeling and pulmonary hypertension progression induced by MCT in rats. AS-IV suppressed the expression of pyroptosis-related markers, the release of pro-inflammatory cytokine interleukin (IL)-1\u03b2 and IL-18 and fibrosis development in pulmonary tissues of PAH rats and in hypoxic PAMSCs. Interestingly, the expression of prolyl-4-hydroxylase 2 (PHD2) was restored by AS-IV administration in PAH model in vivo and in vitro, while hypoxia inducible factor 1\u03b1 (HIF1\u03b1) was restrained by AS-IV. Mechanistically, silencing PHD2 reversed the inhibitory effect of AS-IV on pyroptosis, fibrosis trend and pyroptotic necrosis in hypoxia-cultured PASMCs, while the HIF1\u03b1 inhibitor could prevent these PAH-like phenomena.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Collectively, AS-IV elevates PHD2 expression to alleviate pyroptosis and fibrosis development during PAH through downregulating HIF1\u03b1. These findings may provide a better understanding of AS-IV preventing PAH, and the PHD2\/HIF1\u03b1 axis may be a potential anti-pyroptosis target during PAH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-023-02660-9","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T06:02:22Z","timestamp":1697090542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Astragaloside IV restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2\/HIF1\u03b1 signaling pathway"],"prefix":"10.1186","volume":"23","author":[{"given":"Jie","family":"Xi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"issue":"14","key":"2660_CR1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1089\/ars.2019.7753","volume":"31","author":"DJR Fulton","year":"2019","unstructured":"Fulton DJR, Li X, Bordan Z, Wang Y, Mahboubi K, Rudic RD, et al. Galectin-3: a harbinger of reactive oxygen species, fibrosis, and inflammation in pulmonary arterial hypertension. Antioxid Redox Signal. 2019;31(14):1053\u201369.","journal-title":"Antioxid Redox Signal"},{"issue":"15","key":"2660_CR2","doi-asserted-by":"publisher","first-page":"7321","DOI":"10.1111\/jcmm.16761","volume":"25","author":"R Song","year":"2021","unstructured":"Song R, Lei S, Yang S, Wu SJ. LncRNA PAXIP1-AS1 fosters the pathogenesis of pulmonary arterial hypertension via ETS1\/WIPF1\/RhoA axis. J Cell Mol Med. 2021;25(15):7321\u201334.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"2660_CR3","doi-asserted-by":"publisher","first-page":"H1322","DOI":"10.1152\/ajpheart.00136.2018","volume":"315","author":"T Thenappan","year":"2018","unstructured":"Thenappan T, Chan SY, Weir EK. Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2018;315(5):H1322\u2013h1331.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"2660_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1039\/C8RA07892K","volume":"9","author":"WL Jiang","year":"2018","unstructured":"Jiang WL, Han X, Zhang YF, Xia QQ, Zhang JM, Wang F. Arctigenin prevents monocrotaline-induced pulmonary arterial hypertension in rats. RSC Adv. 2018;9(1):552\u20139.","journal-title":"RSC Adv"},{"key":"2660_CR5","doi-asserted-by":"crossref","unstructured":"Zhou J, Zhou Z, Liu X, Yin HY, Tang Y, Cao X. P2X7 receptor-mediated inflammation in Cardiovascular Disease. Front Pharmacol. 2021; 12654425.","DOI":"10.3389\/fphar.2021.654425"},{"issue":"9","key":"2660_CR6","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1111\/jcmm.13725","volume":"22","author":"W Qian","year":"2018","unstructured":"Qian W, Cai X, Qian Q, Zhang W, Wang D. Astragaloside IV modulates TGF-\u03b21-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. J Cell Mol Med. 2018;22(9):4354\u201365.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"2660_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13046-018-0878-0","volume":"37","author":"F Xu","year":"2018","unstructured":"Xu F, Cui WQ, Wei Y, Cui J, Qiu J, Hu LL, et al. Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling. J Exp Clin Cancer Res. 2018;37(1):207.","journal-title":"J Exp Clin Cancer Res"},{"key":"2660_CR8","doi-asserted-by":"crossref","unstructured":"Tan YQ, Chen HW, Li J, Astragaloside IV. An effective drug for the treatment of Cardiovascular Diseases. Drug Des Devel Ther. 2020; 143731\u20133746.","DOI":"10.2147\/DDDT.S272355"},{"key":"2660_CR9","doi-asserted-by":"crossref","unstructured":"Yao J, Fang X, Zhang C, Yang Y, Wang D, Chen Q et al. Astragaloside IV attenuates hypoxia\u2013induced pulmonary vascular remodeling via the notch signaling pathway. Mol Med Rep. 2021; 23(1).","DOI":"10.3892\/mmr.2020.11726"},{"issue":"2","key":"2660_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3892\/ijmm.2020.4813","volume":"47","author":"H Jin","year":"2021","unstructured":"Jin H, Jiao Y, Guo L, Ma Y, Zhao R, Li X, et al. Astragaloside IV blocks monocrotaline\u2013induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling. Int J Mol Med. 2021;47(2):595\u2013606.","journal-title":"Int J Mol Med"},{"issue":"3","key":"2660_CR11","doi-asserted-by":"publisher","first-page":"L472","DOI":"10.1152\/ajplung.00405.2019","volume":"318","author":"S He","year":"2020","unstructured":"He S, Ma C, Zhang L, Bai J, Wang X, Zheng X, et al. GLI1-mediated pulmonary artery smooth muscle cell pyroptosis contributes to hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2020;318(3):L472\u2013l482.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"6","key":"2660_CR12","doi-asserted-by":"publisher","first-page":"e13048","DOI":"10.1111\/cpr.13048","volume":"54","author":"W Feng","year":"2021","unstructured":"Feng W, Wang J, Yan X, Zhang Q, Chai L, Wang Q, et al. ERK\/Drp1-dependent mitochondrial fission contributes to HMGB1-induced autophagy in pulmonary arterial hypertension. Cell Prolif. 2021;54(6):e13048.","journal-title":"Cell Prolif"},{"issue":"1","key":"2660_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","volume":"115","author":"M Rabinovitch","year":"2014","unstructured":"Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 2014;115(1):165\u201375.","journal-title":"Circ Res"},{"key":"2660_CR14","doi-asserted-by":"crossref","unstructured":"Hu Y, Chi L, Kuebler WM, Goldenberg NM. Perivascular inflammation in pulmonary arterial hypertension. Cells. 2020; 9(11).","DOI":"10.3390\/cells9112338"},{"key":"2660_CR15","doi-asserted-by":"crossref","unstructured":"Foley A, Steinberg BE, Goldenberg NM. Inflammasome activation in pulmonary arterial hypertension. Front Med (Lausanne). 2021; 8826557.","DOI":"10.3389\/fmed.2021.826557"},{"key":"2660_CR16","doi-asserted-by":"crossref","unstructured":"Tang B, Chen GX, Liang MY, Yao JP, Wu ZK. Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats. Int J Cardiol. 2015; 180134\u201341.","DOI":"10.1016\/j.ijcard.2014.11.161"},{"key":"2660_CR17","first-page":"5711","volume":"145699","author":"L Guo","year":"2021","unstructured":"Guo L, Qin G, Cao Y, Yang Y, Dai S, Wang L, et al. Regulation of the Immune Microenvironment by an NLRP3 inhibitor contributes to attenuation of Acute Right Ventricular failure in rats with pulmonary arterial hypertension. J Inflamm Res. 2021;145699:5711.","journal-title":"J Inflamm Res"},{"key":"2660_CR18","doi-asserted-by":"crossref","unstructured":"Qiu Z, He Y, Ming H, Lei S, Leng Y, Xia ZY. Lipopolysaccharide (LPS) aggravates high glucose- and Hypoxia\/Reoxygenation-Induced Injury through activating ROS-Dependent NLRP3 inflammasome-mediated pyroptosis in H9C2 cardiomyocytes. J Diabetes Res. 2019; 20198151836.","DOI":"10.1155\/2019\/8151836"},{"key":"2660_CR19","doi-asserted-by":"crossref","unstructured":"Zeng C, Duan F, Hu J, Luo B, Huang B, Lou X et al. NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. Redox Biol. 2020; 34101523.","DOI":"10.1016\/j.redox.2020.101523"},{"key":"2660_CR20","doi-asserted-by":"crossref","unstructured":"Wang S, Yuan YH, Chen NH, Wang HB. The mechanisms of NLRP3 inflammasome\/pyroptosis activation and their role in Parkinson\u2019s disease. Int Immunopharmacol. 2019; 67458\u2013464.","DOI":"10.1016\/j.intimp.2018.12.019"},{"key":"2660_CR21","doi-asserted-by":"crossref","unstructured":"Qiu Z, Lei S, Zhao B, Wu Y, Su W, Liu M et al. NLRP3 inflammasome activation-mediated pyroptosis aggravates myocardial Ischemia\/Reperfusion Injury in Diabetic rats. Oxid Med Cell Longev. 2017; 20179743280.","DOI":"10.1155\/2017\/9743280"},{"issue":"5","key":"2660_CR22","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1161\/ATVBAHA.120.315525","volume":"41","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Liu H, Yu H, Zhou Y, Zhang J, Xin W, et al. Circular RNA Calm4 regulates Hypoxia-Induced Pulmonary arterial smooth muscle cells pyroptosis via the Circ-Calm4\/miR-124-3p\/PDCD6 Axis. Arterioscler Thromb Vasc Biol. 2021;41(5):1675\u201393.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2660_CR23","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1161\/HYPERTENSIONAHA.121.17868","volume":"79","author":"Y Wu","year":"2022","unstructured":"Wu Y, Pan B, Zhang Z, Li X, Leng Y, Ji Y, et al. Caspase-4\/11-Mediated pulmonary artery endothelial cell pyroptosis contributes to pulmonary arterial hypertension. Hypertension. 2022;79(3):536\u201348.","journal-title":"Hypertension"},{"key":"2660_CR24","doi-asserted-by":"crossref","unstructured":"Zhang M, Xin W, Yu Y, Yang X, Ma C, Zhang H et al. Programmed death-ligand 1 triggers PASMCs pyroptosis and pulmonary vascular fibrosis in pulmonary hypertension. J Mol Cell Cardiol. 2020; 13823\u201333.","DOI":"10.1016\/j.yjmcc.2019.10.008"},{"key":"2660_CR25","doi-asserted-by":"crossref","unstructured":"Leng B, Zhang Y, Liu X, Zhang Z, Liu Y, Wang H et al. Astragaloside IV suppresses high Glucose-Induced NLRP3 inflammasome activation by inhibiting TLR4\/NF-\u03baB and CaSR. Mediators Inflamm 2019; 20191082497.","DOI":"10.1155\/2019\/1082497"},{"key":"2660_CR26","doi-asserted-by":"crossref","unstructured":"Xiao L, Dai Z, Tang W, Liu C, Tang B. Astragaloside IV alleviates cerebral ischemia-reperfusion Injury through NLRP3 inflammasome-mediated pyroptosis inhibition via activating Nrf2. Oxid Med Cell Longev. 2021; 20219925561.","DOI":"10.1155\/2021\/9925561"},{"issue":"3","key":"2660_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/glia.23109","volume":"65","author":"Y Hirayama","year":"2017","unstructured":"Hirayama Y, Koizumi S. Hypoxia-independent mechanisms of HIF-1\u03b1 expression in astrocytes after ischemic preconditioning. Glia. 2017;65(3):523\u201330.","journal-title":"Glia"},{"key":"2660_CR28","doi-asserted-by":"crossref","unstructured":"Xu WN, Zheng HL, Yang RZ, Jiang LS, Jiang SD. HIF-1\u03b1 regulates Glucocorticoid-Induced osteoporosis through PDK1\/AKT\/mTOR signaling pathway. Front Endocrinol (Lausanne). 2019; 10922.","DOI":"10.3389\/fendo.2019.00922"},{"issue":"1","key":"2660_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.chest.2016.09.001","volume":"151","author":"KJ Dunham-Snary","year":"2017","unstructured":"Dunham-Snary KJ, Wu D, Sykes EA, Thakrar A, Parlow LRG, Mewburn JD, et al. Hypoxic pulmonary vasoconstriction: from Molecular Mechanisms to Medicine. Chest. 2017;151(1):181\u201392.","journal-title":"Chest"},{"issue":"1","key":"2660_CR30","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1038\/s41467-019-11500-6","volume":"10","author":"Y Luo","year":"2019","unstructured":"Luo Y, Teng X, Zhang L, Chen J, Liu Z, Chen X, et al. CD146-HIF-1\u03b1 hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension. Nat Commun. 2019;10(1):3551.","journal-title":"Nat Commun"},{"issue":"2","key":"2660_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10456-021-09828-z","volume":"25","author":"H Elamaa","year":"2022","unstructured":"Elamaa H, Kaakinen M, N\u00e4tynki M, Szabo Z, Ronkainen VP, \u00c4ij\u00e4l\u00e4 V, et al. PHD2 deletion in endothelial or arterial smooth muscle cells reveals vascular cell type-specific responses in pulmonary hypertension and fibrosis. Angiogenesis. 2022;25(2):259\u201374.","journal-title":"Angiogenesis"},{"issue":"1","key":"2660_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ajpath.2018.09.012","volume":"189","author":"Q Fan","year":"2019","unstructured":"Fan Q, Mao H, Xie L, Pi X. Prolyl Hydroxylase Domain-2 protein regulates Lipopolysaccharide-Induced vascular inflammation. Am J Pathol. 2019;189(1):200\u201313.","journal-title":"Am J Pathol"},{"key":"2660_CR33","doi-asserted-by":"crossref","unstructured":"Zhu J, Zhao L, Hu Y, Cui G, Luo A, Bao C et al. Hypoxia-inducible factor 2-Alpha mediated gene sets differentiate pulmonary arterial hypertension. Front Cell Dev Biol. 2021; 9701247.","DOI":"10.3389\/fcell.2021.701247"},{"issue":"13","key":"2660_CR34","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1093\/cvr\/cvz312","volume":"116","author":"J Zhang","year":"2020","unstructured":"Zhang J, Lu X, Liu M, Fan H, Zheng H, Zhang S, et al. Melatonin inhibits inflammasome-associated activation of endothelium and macrophages attenuating pulmonary arterial hypertension. Cardiovasc Res. 2020;116(13):2156\u201369.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2660_CR35","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/jcmm.15671","volume":"25","author":"Y Sun","year":"2021","unstructured":"Sun Y, Lu M, Sun T, Wang H. Astragaloside IV attenuates inflammatory response mediated by NLRP-3\/calpain-1 is involved in the development of pulmonary hypertension. J Cell Mol Med. 2021;25(1):586\u201390.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"2660_CR36","doi-asserted-by":"publisher","first-page":"204589402097491","DOI":"10.1177\/2045894020974919","volume":"10","author":"Z Wu","year":"2020","unstructured":"Wu Z, Geng J, Qi Y, Li J, Bai Y, Guo Z. MiR-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4. Pulm Circ. 2020;10(4):2045894020974919.","journal-title":"Pulm Circ"},{"issue":"4","key":"2660_CR37","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ajpath.2010.12.016","volume":"178","author":"LJ Duan","year":"2011","unstructured":"Duan LJ, Takeda K, Fong GH. Prolyl hydroxylase domain protein 2 (PHD2) mediates oxygen-induced retinopathy in neonatal mice. Am J Pathol. 2011;178(4):1881\u201390.","journal-title":"Am J Pathol"},{"key":"2660_CR38","doi-asserted-by":"crossref","unstructured":"Guan D, Li C, Li Y, Li Y, Wang G, Gao F et al. The DpdtbA induced EMT inhibition in gastric cancer cell lines was through ferritinophagy-mediated activation of p53 and PHD2\/hif-1\u03b1 pathway. J Inorg Biochem. 2021; 218111413.","DOI":"10.1016\/j.jinorgbio.2021.111413"},{"issue":"4","key":"2660_CR39","doi-asserted-by":"publisher","first-page":"L675","DOI":"10.1152\/ajplung.00351.2020","volume":"321","author":"B Kassa","year":"2021","unstructured":"Kassa B, Kumar R, Mickael C, Sanders L, Vohwinkel C, Lee MH, et al. Endothelial cell PHD2-HIF1\u03b1-PFKFB3 contributes to right ventricle vascular adaptation in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2021;321(4):L675\u2013l685.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"2660_CR40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41401-018-0076-9","volume":"40","author":"HM Liu","year":"2019","unstructured":"Liu HM, Jia Y, Zhang YX, Yan J, Liao N, Li XH, et al. Dysregulation of miR-135a-5p promotes the development of rat pulmonary arterial hypertension in vivo and in vitro. Acta Pharmacol Sin. 2019;40(4):477\u201385.","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"2660_CR41","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1530\/EC-20-0295","volume":"9","author":"L Zhou","year":"2020","unstructured":"Zhou L, Zhang R, Yang S, Zhang Y, Shi D. Astragaloside IV alleviates placental oxidative stress and inflammation in GDM mice. Endocr Connect. 2020;9(9):939\u201345.","journal-title":"Endocr Connect"},{"issue":"1\u20132","key":"2660_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11010-020-03743-5","volume":"470","author":"Y Wu","year":"2020","unstructured":"Wu Y, Fan Z, Chen Z, Hu J, Cui J, Liu Y, et al. Astragaloside IV protects human cardiomyocytes from hypoxia\/reoxygenation injury by regulating miR-101a. Mol Cell Biochem. 2020;470(1\u20132):41\u201351.","journal-title":"Mol Cell Biochem"},{"key":"2660_CR43","doi-asserted-by":"crossref","unstructured":"Jin H, Wang L, Li B, Cai C, Ye J, Xia J et al. Astragaloside IV ameliorates airway inflammation in an established murine model of Asthma by inhibiting the mTORC1 Signaling Pathway. Evid Based Complement Alternat Med. 2017; 20174037086.","DOI":"10.1155\/2017\/4037086"},{"issue":"1","key":"2660_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-020-02040-8","volume":"18","author":"Y Li","year":"2021","unstructured":"Li Y, Song W, Tong Y, Zhang X, Zhao J, Gao X, et al. Isoliquiritin ameliorates depression by suppressing NLRP3-mediated pyroptosis via miRNA-27a\/SYK\/NF-\u03baB axis. J Neuroinflammation. 2021;18(1):1.","journal-title":"J Neuroinflammation"},{"issue":"10","key":"2660_CR45","doi-asserted-by":"publisher","first-page":"9405","DOI":"10.18632\/aging.103215","volume":"12","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhang Y, Li R, Zhu L, Fu B, Yan T. Salidroside ameliorates Parkinson\u2019s disease by inhibiting NLRP3-dependent pyroptosis. Aging. 2020;12(10):9405\u201326.","journal-title":"Aging"},{"key":"2660_CR46","doi-asserted-by":"crossref","unstructured":"Yu ZW, Zhang J, Li X, Wang Y, Fu YH, Gao XY. A new research hot spot: the role of NLRP3 inflammasome activation, a key step in pyroptosis, in diabetes and diabetic complications. Life Sci. 2020; 240117138.","DOI":"10.1016\/j.lfs.2019.117138"},{"issue":"2","key":"2660_CR47","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41419-017-0257-3","volume":"9","author":"X Wu","year":"2018","unstructured":"Wu X, Zhang H, Qi W, Zhang Y, Li J, Li Z, et al. Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis. Cell Death Dis. 2018;9(2):171.","journal-title":"Cell Death Dis"},{"issue":"2","key":"2660_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1165\/rcmb.2015-0231TR","volume":"54","author":"S Lee","year":"2016","unstructured":"Lee S, Suh GY, Ryter SW, Choi AM. Regulation and function of the nucleotide binding domain leucine-rich repeat-containing receptor, pyrin domain-Containing-3 Inflammasome in Lung Disease. Am J Respir Cell Mol Biol. 2016;54(2):151\u201360.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2660_CR49","doi-asserted-by":"crossref","unstructured":"Neary R, Watson CJ, Baugh JA. Epigenetics and the overhealing wound: the role of DNA methylation in fibrosis. Fibrogenesis Tissue Repair. 2015; 818.","DOI":"10.1186\/s13069-015-0035-8"},{"issue":"6","key":"2660_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/scrt512","volume":"5","author":"A Birbrair","year":"2014","unstructured":"Birbrair A, Zhang T, Files DC, Mannava S, Smith T, Wang ZM, et al. Type-1 pericytes accumulate after tissue injury and produce collagen in an organ-dependent manner. Stem Cell Res Ther. 2014;5(6):122.","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"2660_CR51","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tips.2022.04.003","volume":"43","author":"RC Coll","year":"2022","unstructured":"Coll RC, Schroder K, Pelegr\u00edn P. NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci. 2022;43(8):653\u201368.","journal-title":"Trends Pharmacol Sci"},{"key":"2660_CR52","doi-asserted-by":"crossref","unstructured":"Wu Z, Zhou G, Wang H, Yao P. Inhibition of KIF23 alleviates IPAH by targeting pyroptosis and proliferation of PASMCs. Int J Mol Sci. 2022; 23(8).","DOI":"10.3390\/ijms23084436"},{"issue":"9","key":"2660_CR53","doi-asserted-by":"publisher","first-page":"4670","DOI":"10.1096\/fj.201701139R","volume":"32","author":"B Luo","year":"2018","unstructured":"Luo B, Xiang D, Wu D, Liu C, Fang Y, Chen P, et al. Hepatic PHD2\/HIF-1\u03b1 axis is involved in postexercise systemic energy homeostasis. Faseb j. 2018;32(9):4670\u201380.","journal-title":"Faseb j"},{"key":"2660_CR54","doi-asserted-by":"crossref","unstructured":"Chen T, Zhou Q, Tang H, Bozkanat M, Yuan JX, Raj JU et al. miR-17\/20 controls Prolyl hydroxylase 2 (PHD2)\/Hypoxia-Inducible factor 1 (HIF1) to regulate pulmonary artery smooth muscle cell proliferation. J Am Heart Assoc. 2016; 5(12).","DOI":"10.1161\/JAHA.116.004510"},{"issue":"7","key":"2660_CR55","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.celrep.2017.01.051","volume":"18","author":"G Di Conza","year":"2017","unstructured":"Di Conza G, Trusso Cafarello S, Loroch S, Mennerich D, Deschoemaeker S, Di Matteo M, et al. The mTOR and PP2A pathways regulate PHD2 phosphorylation to Fine-Tune HIF1\u03b1 levels and colorectal Cancer cell survival under Hypoxia. Cell Rep. 2017;18(7):1699\u2013712.","journal-title":"Cell Rep"},{"issue":"39","key":"2660_CR56","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1038\/onc.2017.158","volume":"36","author":"JY Lee","year":"2017","unstructured":"Lee JY, Park JH, Choi HJ, Won HY, Joo HS, Shin DH, et al. LSD1 demethylates HIF1\u03b1 to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis. Oncogene. 2017;36(39):5512\u201321.","journal-title":"Oncogene"},{"key":"2660_CR57","doi-asserted-by":"crossref","unstructured":"Lee G, Won HS, Lee YM, Choi JW, Oh TI, Jang JH et al. Oxidative dimerization of PHD2 is responsible for its inactivation and contributes to metabolic reprogramming via HIF-1\u03b1 activation. Sci Rep. 2016; 618928.","DOI":"10.1038\/srep18928"},{"issue":"6","key":"2660_CR58","first-page":"2940","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J, Sheng Z, Cai Y. SIRT6 overexpression inhibits HIF1\u03b1 expression and its impact on tumor angiogenesis in lung cancer. Int J Clin Exp Pathol. 2018;11(6):2940\u20137.","journal-title":"Int J Clin Exp Pathol"},{"key":"2660_CR59","doi-asserted-by":"crossref","unstructured":"Jiang Q, Geng X, Warren J, Eugene Paul Cosky E, Kaura S, Stone C et al. Hypoxia Inducible Factor-1\u03b1 (HIF-1\u03b1) mediates NLRP3 inflammasome-dependent-pyroptotic and apoptotic cell death following ischemic stroke. Neuroscience. 2020; 448126\u2013139.","DOI":"10.1016\/j.neuroscience.2020.09.036"},{"issue":"24","key":"2660_CR60","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1161\/CIRCULATIONAHA.116.021494","volume":"133","author":"Z Dai","year":"2016","unstructured":"Dai Z, Li M, Wharton J, Zhu MM, Zhao YY. Prolyl-4 hydroxylase 2 (PHD2) Deficiency in endothelial cells and hematopoietic cells induces obliterative vascular remodeling and severe pulmonary arterial hypertension in mice and humans through hypoxia-inducible Factor-2\u03b1. Circulation. 2016;133(24):2447\u201358.","journal-title":"Circulation"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02660-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02660-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02660-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T13:03:26Z","timestamp":1700312606000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02660-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2660"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02660-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]},"assertion":[{"value":"31 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The experiment protocol was approved by Medical Ethics Committee of Urumqi Youai Hospital, and all the operations followed the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and ARRIVE Guidelines pertaining to animal experimentation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"386"}}